You are here Home Vaccines Vaccines Vaxigrip Tetra Details for Vaxigrip Tetra (influenza) vaccine and its components. Listen Print Share Twitter Facebook Email Recently added This page was added on 04 June 2018. Updates made This page was updated on [date-counter-updated-date]. View history of updates Sponsor Sanofi-Aventis Australia Administration route Intramuscular injection Subcutaneous injection Vaccine group All people aged ≥6 months Description: Registered for use in people aged ≥6 months. Quadrivalent inactivated influenza vaccine, split virion. Each 0.5 mL monodose pre-filled syringe contains: 15 µg haemagglutinin of each of the 4 recommended influenza virus strains May contain traces of: ovalbumin (≤ 0.05 µg) neomycin (≤ 10.1 pg) formaldehyde (≤ 30 µg) octoxinol-9 (≤ 222.5 µg) For Product Information and Consumer Medicine Information about Vaxigrip Tetra visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s. Related diseases Influenza (flu) Page history Last updated 11 May 2023 Last reviewed 11 May 2023 Is there anything wrong with this page? Help us improve the Australian Immunisation Handbook What you were doing? (required) What went wrong? (required) Leave this field blank
